Ghrelin Hormone Protects Against Muscle Loss During Lung Infections in Aging
Study shows ghrelin treatment preserved muscle mass and strength in aged mice with lung inflammation, offering hope for sarcopenia prevention.
Summary
Researchers found that ghrelin, a hormone produced in the stomach, can protect against muscle loss during lung infections in aging. In aged mice with induced lung inflammation, ghrelin treatment preserved muscle weight and mass, improved muscle strength, and increased voluntary activity. The hormone worked by suppressing proteins that break down muscle tissue and reducing inflammatory damage. Ghrelin also decreased lung inflammation and protected muscle cells from oxidative stress in laboratory studies. This research suggests ghrelin could be a promising treatment for sarcopenia, the age-related loss of muscle mass that affects mobility and increases mortality risk in older adults.
Detailed Summary
Sarcopenia, the progressive loss of muscle mass and strength with aging, becomes particularly dangerous when combined with respiratory infections like pneumonia. This condition affects mobility, increases frailty, and raises mortality risk in older adults, yet no effective treatments currently exist.
Japanese researchers investigated whether ghrelin, a stomach-produced hormone known for stimulating appetite and reducing inflammation, could protect against muscle loss during lung infections. They studied aged male mice given lipopolysaccharide to induce lung inflammation, treating half with ghrelin injections every 12 hours.
Ghrelin treatment produced remarkable protective effects. Treated mice maintained muscle weight and mass compared to untreated controls, showed improved muscle contractile force, and demonstrated increased voluntary wheel-running activity. The hormone suppressed FoxO1-dependent expression of muscle-degrading proteins and reduced inflammatory cytokines in lung fluid. Laboratory studies on muscle cells revealed ghrelin decreased oxidative stress and increased expression of protective antioxidant genes.
These findings suggest ghrelin could become a therapeutic intervention for respiratory sarcopenia in elderly patients. The hormone's dual action of preserving muscle tissue while reducing lung inflammation addresses both local and systemic aspects of infection-related muscle wasting. However, this research was conducted only in male mice, and human studies are needed to confirm safety and efficacy. The optimal dosing, timing, and long-term effects of ghrelin treatment remain to be determined before clinical applications can be considered.
Key Findings
- Ghrelin treatment preserved muscle mass and strength in aged mice with lung inflammation
- The hormone suppressed muscle-degrading proteins while reducing lung inflammatory markers
- Ghrelin protected muscle cells from oxidative stress and increased antioxidant gene expression
- Treated mice showed improved voluntary physical activity compared to controls
Methodology
Controlled study using aged male mice with lipopolysaccharide-induced lung injury, comparing ghrelin treatment (every 12 hours) versus controls. Included muscle tissue analysis, contractile force measurements, and in vitro studies using C2C12 muscle cells.
Study Limitations
Study conducted only in male mice, limiting generalizability to humans and females. Long-term safety, optimal dosing protocols, and clinical efficacy in humans remain unknown and require further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.